Market revenue in 2020 | USD 485.7 million |
Market revenue in 2028 | USD 1,345.6 million |
Growth rate | 13.6% (CAGR from 2020 to 2028) |
Largest segment | Oral |
Fastest growing segment | Injectable |
Historical data | 2017 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Topical, Injectable, Oral |
Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Oral was the largest segment with a revenue share of 38.32% in 2020. Horizon Databook has segmented the Germany atopic dermatitis drugs market based on topical, injectable, oral covering the revenue growth of each sub-segment from 2017 to 2028.
Germany has a strong healthcare system, which covers 90% of the population under mandatory health insurance. Thereby, access to atopic dermatitis treatment in this country is relatively easier. Increasing R&D in the country on atopic dermatitis to develop novel treatments is accelerating its market.
For instance, as per British Journal of Dermatology, in 2020, noninterventional study TREAT Germany, a German atopic eczema registry, studied the effectiveness of treatment regimes in patients. New entrant biologic drug Dupilumab demonstrated clinical effectiveness in these studies.
Local presence of key players, such as Bayer, is expected to boost the country’s market. For instance, Evotec AG entered into a collaboration with Almirall for developing durable and potent treatments for dermatological conditions such as atopic dermatitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Germany atopic dermatitis drugs market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account